Videos

Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.

Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.

Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.

Daniel George, MD, discusses results from a study analyzing real-world utilization of advanced therapies for patients with metastatic CSPC over time by metastatic site and age.

David Chun Cheong Tsui, MD, discusses results from a real-world study exploring the adoption and early clinical outcomes of atezolizumab plus carboplatin and etoposide in patients with extensive-stage SCLC.

Kerry Rogers, MD, discusses real-world treatment patterns and health care costs among patients with CLL or SLL who received venetoclax.

Theresa Schmidt, MA, and Kimberly Westrich, MA, discuss the role of patient-reported measures and value-based payment models in patient-centered cancer care.

Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.

Frederick Schnell, MD, FACP; Bo Gamble; and John Cox, DO, MBA, FACP, FASCO, discuss the ASCO-COA Oncology Medical Home standards, current quality initiatives for cancer care delivery, and where quality initiatives are advancing in the future.

Christian Buske, MD, discusses data surrounding ibrutinib for the treatment of Waldenström macroglobulinemia.